Author: Editor

Clemens Wendtner, MD of Klinikum Schwabing, Munich, Germany, highlights key advances in the field of chronic lymphocytic leukemia (CLL) discussed at the German CLL Study Group (GCLLSG) 2016 meeting. Dr Wendtner mentions the importance of subclones in CLL, new kinase inhibitor combinations, and immunotherapy. Using checkpoint inhibitors combined with immunostimulatory drugs may be a new avenue in CLL research. Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.

Barbara Eichhorst, MD of the University of Cologne, Cologne, Germany, how to take care of the mental well-being of chronic lymphocytic leukemia (CLL) patients. For patients in the wach-and-wait period, particularly in the first year, it helps if they are seen on a regular basis; it is important for them to build and maintain self-confidence. It is important to make sure they get their vaccinations and that after the first 1-2 years, if they have s a slowly progressing CLL, that they are mentally stable. For those patients who receive a long, continuous therapy, it is essential to monitor them…

World-renowned MPN expert Dr. Ruben Mesa of Mayo Clinic discusses the recently updated NCCN guidelines that help advise doctors around the world on how to treat MPNs. Watch to hear Dr. Mesas explanation of how these are used in practice and how the guidelines have evolved over time. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

In this video, Drs. Morton Coleman and John P. Leonard summarize the key take-home points presented on lymphoma during Lymphoma & Myeloma 2016: An International Congress on Hematologic Malignancies, and examine their clinical implications. Earn CME credit for this activity at the following location: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7227 © 2016 Imedex, LLC.

In this video, Drs. Morton Coleman and Richard R. Furman summarize the key take-home points presented on CLL during Lymphoma & Myeloma 2016: An International Congress on Hematologic Malignancies, and examine their clinical implications. Earn CME credit for this activity at the following location: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7226 © 2016 Imedex, LLC.

In this video Drs. Morton Coleman and Ruben Niesvizky summarize the key take-home points presented on multiple myeloma during Lymphoma & Myeloma 2016: An International Congress on Hematologic Malignancies, and examine their clinical implications. Earn CME credit for this activity at the following location: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7225 © 2016 Imedex, LLC.

Raquibul Hannan, MD Radiation Oncologist, University of Texas Southwestern discusses SABR and immunotherapy.

Raquibul Hannan, MD Radiation Oncologist, University of Texas Southwestern discusses Utilizing SABR in the oligo-metastatic disease.

Raquibul Hannan, MD Radiation Oncologist, University of Texas Southwestern discusses SABR in locally advanced RCC and oligo-metastatic disease.

Raquibul Hannan, MD Radiation Oncologist, University of Texas Southwestern discusses What is the role of SABR in CNS mets in RCC.

Eric Jonasch, MD of MD Anderson gives an overview of several presentations covering the Understanding Molecular Subtypes of Non-Clear Cell RCC.

Chung-Han Lee, MD, PhD, Medical Oncologist, Memorial Sloan Kettering interview on Medullary Renal Cell Carcinoma (RCC): Genomics and Treatment Outcomes.

Ithaar H. Derweesh, M.D., University of California, San Diego discusses neoadjuvant therapy for patients with metastatic disease and extra renal burden.

Ithaar H. Derweesh, M.D., University of California, San Diego discusses the historical data for neoadjuvant therapy in RCC.

Guru Sonpavde, MD, Associate Professor of Medicine Director, Urologic Oncology, UAB Comprehensive Cancer Center notes that More Single Agent Therapy needed in Kidney Cancer.

Guru Sonpavde, MD, Associate Professor of Medicine Director, Urologic Oncology, UAB Comprehensive Cancer Center discusses VEGF followed by PD-1 inhibition or PD-1 inhibition followed by VEGF.

Guru Sonpavde, MD, Associate Professor of Medicine Director, Urologic Oncology, UAB Comprehensive Cancer Center answers the question Why would sequencing VEGF and PD-1 inhibition be a better option than combination therapy in Kidney Cancer.

David McDermott, MD of Dana Farber discusses toxicity concerns with the combination VEGF PD-1.

David McDermott, MD of Dana Farber answers the question Why VEGF + PD-1 are logical choices for combination therapy in mRCC?

Naomi B. Haas, MD, Director, Prostate and Kidney Cancer Program, Associate Professor of Medicine at the Hospital of the University of Pennsylvania discusses the Current State of Adjuvant Therapy in Kidney Cancer.

Are memory issues typical for patients with myelofibrosis? Is aspirin the answer? In this Ask the Expert segment, Dr. Prithviraj Bose from The University of Texas MD Anderson Cancer Center, responds to a viewer question related to trouble concentrating and memory lapses associated with myeloproliferative neoplasms (MPNs). Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Dr. Sima Porten, MD MPH, Assistant Professor, Department of Urology UCSF answers the question What are some of the limitations of partial nephrectomies?

Dr. Sima Porten, MD MPH, Assistant Professor, Department of Urology UCSF answers the question What patients should be selected for partial nephrectomy?

Kamran Ahrar, MD, MBA, Professor, Interventional Radiology answers the question Why is renal tumor ablation underutilized?

Kamran Ahrar, MD, MBA, Professor, Interventional Radiology answers the question what is the current role of renal tumor ablation?

hillip M. Pierorazio, MD, Assistant Professor of Urology and Oncology, Brady Urological Institute, Sidney Kimmel Cancer Center, Johns Hopkins Hospital recaps the active surveillance study primary results.

Phillip Pierorazio, MD, Assistant Professor of Urology and Oncology, Brady Urological Institute, Sidney Kimmel Cancer Center, Johns Hopkins Hospital outlines the John Hopkins active surveillance study for renal masses.

Dr. Daniel Heng MD @DrDanielHeng University of Calgary discusses genomic investigation in the ASSURE and S-TRAC adjuvant trials.

Daniel Heng, MD University of Calgary @DrDanielHeng describes what is the role of genomic investigation in predicting recurrence of local RCC.

Alexander Kutikov, MD, FACS, Associate Professor of Urologic Oncology Fox Chase Cancer Center answers the question of what is the algorithmfor for proceeding with renal mass biopsy.

Alexander Kutikov, MD, FACS explains the current standards of care for renal mass biopsies at the 2016 annual International Kidney Cancer Symposium.

Aly-Khan A. Lalani, MD of the University of Alberta gives a quick overview of the latest in Proton Pump Inhibitors in mRCC.

Paula Ragan, CEO of X4 Pharmaceuticals gives a quick overview of her presentation at the 2016 annual International Kidney Cancer Symposium.

Professor Thomas Powles MBBS, MRCP, MD, Barts Cancer Institute presents Clinical outcomes based on MET expression level in METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in advanced renal cell carcinoma (RCC) at the 2016 annual International Kidney Cancer Symposium.

Toni K. Choueiri, MD, Director and Disease Center Leader, The Lank Center for Genitourinary Oncology, President of Medical Staff, Dana-Farber Cancer Institute accepts the Schonfeld award at the 2016 annual International Kidney Cancer Symposium.

Brian I. Rini, M.D., Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center presents Axitinib is an Ideal Choice in Refractory Renal Cell Carcinoma.

Thomas E Hutson, DO, PharmD FACP Director, GU Oncology Program, Co-Director, Urologic Cancer Research and Treatment Center, Texas Oncology/ Baylor Sammons Cancer Center, Professor of Medicine, Texas AM College of Medicine presents LENVATINIB + EVEROLIMUS A powerful treatment for refractory RCC at the 2016 annual International Kidney Cancer Symposium.

Nizar M. Tannir, MD, FACP, Professor and Deputy Chair, GU Medical Oncology, MD Anderson presents Cabozantinib is the best salvage therapy for RCC at the 2016 annual International Kidney Cancer Symposium.

Saby George, MD, FACP, Associate Professor of Medicine and Oncology, Genitourinary Oncology Program , Roswell Park Cancer Institute presents Nivolumab as a second-line therapy for metastatic RCC at the 2016 annual International Kidney Cancer Symposium.

HIF-2 Inhibitor discussion at the 2016 annual International Kidney Cancer Symposium.

… 77 year WF presents with back painHistory of renal cell carcinoma, s/p right radical nephrectomy in 2000T1bN0M0 Clear cell renal cell carcinomaStopped surveillance after 5 yearsPMH: HyperlipidemiaPSH: nephrectomy, hysterectomyCT chest: NegativeLabs: eGFR 56, otherwise WNL 80 year old WM presents with chronic constipation and abdominal painPMH: DM II, HtnPSH: Left ankleLabs: Hb 10.6, Glucose 246, Cr 1.13Presents to our EC with worsening bilateral LE edema 79 year old WM presents with gross hematuriaPMH: HypertensionPSH: hernia repair and varicocele repairLabs: Hb 12.6, ESR 78, LDH 429Was enrolled in the randomized phase II presurgical immune checkpoint blockade trial (2013-0715).Randomized to nivolumab…

Bernard Escudier, Institut Gustave Roussy presents Developing the next generation of studies in RCC at the 2016 annual International Kidney Cancer Symposium.

James Brugarolas, M.D., Ph.D., Kidney Cancer Program Leader, Virginia Murchison Linthicum Endowed Scholar, Associate Professor of Internal Medicine University of Texas Southwestern Medical Center at the 2016 annual International Kidney Cancer Symposium.

Axel Bex, MD, PhD, The Netherlands Cancer Institute presents Durable Responses: How Do We Get There? The role of metastasectomy at the 2016 annual International Kidney Cancer Symposium.

Dylan Martini, MD, Dana-Farber Cancer Institute presents Outcomes in PD-1/PD-L1 inh. responders who discontinued therapy for immune-related adverse events: Analysis of nine patients with metastatic renal cell carcinoma at the 2016 annual International Kidney Cancer Symposium.

James J. Hsieh, MD, PhD, Memorial Sloan Kettering Cancer Center presents Differential Overall Survival Results in RECORD-3 Study Based on Three Distinct Clear Cell Metastatic Renal Cell Carcinoma Molecular Subgroups Classified by BAP1 and/or PBRM1 Mutations at the 2016 annual International Kidney Cancer Symposium.

Lana Hamieh, MD, Research Fellow in Medicine (EXT) presents Characterization of Patients with Poor-Risk Metastatic Renal Cell Carcinoma at the 2016 annual International Kidney Cancer Symposium.

Jun Gong, Fellow, City of Hope presents Latency of potential treatment-related adverse events among patients treated with TKI/VEGF-directed therapy for metastatic renal cell carcinoma (mRCC) at the 2016 annual International Kidney Cancer Symposium.

Jill Rachel Mains, MD, Dept. of Radiology and Oncology, Aarhus University Hospital presents Baseline Low B-value Diffusion-weighted Magnetic Resonance Imaging is Prognostic in Metastatic Renal Cell Carcinoma and Correlates with Dynamic Contrast-enhanced Ultrasound and Dynamic Contrast-enhanced Computed Tomography: Results from the DARENCA-1 Study at the 2016 annual International Kidney Cancer Symposium.

Rana McKay, MD, Dana-Farber, presents Impact of Aspirin and Non-Aspirin NSAIDs on Outcomes in Metastatic RCC at the 2016 annual International Kidney Cancer Symposium.